Catalyst Wire Dossier Catalyst Wire Dossier

ARI-3037MO

· Arisaph Pharmaceuticals Inc.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ARI-3037MO, covering 2016-08-08 to 2016-08-08. Get the full timeline:

Most recent: Clinical Trial Update: Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia [Phase 2]

See pricing